Aliases & Classifications for Macular Retinal Edema

MalaCards integrated aliases for Macular Retinal Edema:

Name: Macular Retinal Edema 12 15 73
Macular Edema 12 37 29 55 15
Macular Edema, Cystoid 73

Classifications:



External Ids:

Disease Ontology 12 DOID:4449
MeSH 44 D008269
NCIt 50 C35468
SNOMED-CT 68 37231002
KEGG 37 H01651

Summaries for Macular Retinal Edema

MalaCards based summary : Macular Retinal Edema, also known as macular edema, is related to diabetic macular edema and retinal vein occlusion, and has symptoms including edema and peau d'orange. An important gene associated with Macular Retinal Edema is MFRP (Membrane Frizzled-Related Protein), and among its related pathways/superpathways are Fluid shear stress and atherosclerosis and Spinal Cord Injury. The drugs Bevacizumab and Triamcinolone have been mentioned in the context of this disorder. Affiliated tissues include eye, endothelial and retina, and related phenotype is vision/eye.

Related Diseases for Macular Retinal Edema

Diseases related to Macular Retinal Edema via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 219)
# Related Disease Score Top Affiliating Genes
1 diabetic macular edema 33.5 CCL2 ICAM1 IL6 VEGFA
2 retinal vein occlusion 31.6 CCL2 IL6 VEGFA
3 central retinal vein occlusion 31.5 IL6 VEGFA
4 retinitis pigmentosa 31.4 BEST1 CAPN5 CRB1 MAK MFRP PDE6A
5 uveitis 30.9 CAPN5 CCL2 ICAM1
6 macular dystrophy, dominant cystoid 30.8 BEST1 CAPN5 CRB1 MAK MFRP MRAP
7 vitreous detachment 30.8 KCNMA1 VEGFA
8 microvascular complications of diabetes 1 30.6 CCL2 ICAM1 VEGFA
9 retinal vascular disease 30.4 CCL2 ICAM1 VEGFA
10 coats disease 30.3 CRB1 VEGFA
11 poems syndrome 30.2 IL6 VEGFA
12 macular holes 30.2 CCL2 KCNMA1 VEGFA
13 posterior uveitis 30.1 CAPN5 IL6
14 macular degeneration, age-related, 1 30.0 BEST1 CCL2 CRB1 FANCG KCNMA1 VEGFA
15 retinal artery occlusion 30.0 IL6 VEGFA
16 fundus dystrophy 30.0 BEST1 CRB1 MFRP
17 endophthalmitis 29.8 ICAM1 MRAP VEGFA
18 eales disease 29.8 IL6 VEGFA
19 optic disk drusen 29.7 CRB1 KCNMA1 MFRP VEGFA
20 retinal disease 29.6 BEST1 CRB1 PDE6A
21 rheumatoid arthritis 29.3 CCL2 ICAM1 IL6 VEGFA
22 pars planitis 11.4
23 vitreoretinopathy, neovascular inflammatory 11.4
24 vitreoretinochoroidopathy 11.2
25 cataract 10.8
26 microvascular complications of diabetes 5 10.8
27 retinitis 10.7
28 leber congenital amaurosis 4 10.6
29 retinal detachment 10.5
30 microvascular complications of diabetes 2 10.5
31 melanoma 10.3
32 ischemia 10.3
33 diabetes mellitus 10.3
34 telangiectasis 10.3
35 optic nerve disease 10.3
36 neuropathy 10.3
37 degos 'en cocarde' erythrokeratoderma 10.3
38 gyrate atrophy of choroid and retina 10.3
39 cytomegalovirus retinitis 10.3
40 intermediate uveitis 10.2
41 retinal telangiectasia 10.2 CRB1 VEGFA
42 hydrocele 10.2 ICAM1 VEGFA
43 papilledema 10.2
44 critical limb ischemia 10.2 IL6 VEGFA
45 leukostasis 10.2 ICAM1 VEGFA
46 spinal disease 10.1 IL6 VEGFA
47 peripheral retinal degeneration 10.1 BEST1 KCNMA1
48 juvenile ankylosing spondylitis 10.1 IL6 MRAP
49 primary effusion lymphoma 10.1 IL6 VEGFA
50 multiple sclerosis 10.1

Graphical network of the top 20 diseases related to Macular Retinal Edema:



Diseases related to Macular Retinal Edema

Symptoms & Phenotypes for Macular Retinal Edema

UMLS symptoms related to Macular Retinal Edema:


edema, peau d'orange

MGI Mouse Phenotypes related to Macular Retinal Edema:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 vision/eye MP:0005391 9.17 BEST1 CRB1 ICAM1 IL6 MFRP PDE6A

Drugs & Therapeutics for Macular Retinal Edema

Drugs for Macular Retinal Edema (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 356)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Bevacizumab Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 216974-75-3
2
Triamcinolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 124-94-7 31307
3
Ranibizumab Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 347396-82-1 459903
4
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 50-02-2 5743
5
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 1177-87-3
6
Dorzolamide Approved Phase 4,Phase 2 120279-96-1 5284549 3154
7
Acarbose Approved, Investigational Phase 4 56180-94-0 441184
8
Pioglitazone Approved, Investigational Phase 4,Phase 2 111025-46-8 4829
9
Acetazolamide Approved, Vet_approved Phase 4,Phase 2 59-66-5 1986
10
Prednisolone Approved, Vet_approved Phase 4,Phase 2,Phase 3 50-24-8 5755
11
Prednisolone phosphate Approved, Vet_approved Phase 4,Phase 2,Phase 3 302-25-0
12
Loteprednol Approved, Experimental Phase 4,Not Applicable 82034-46-6, 129260-79-3 9865442 444025
13
Methylprednisolone hemisuccinate Approved Phase 4,Phase 2,Phase 3 2921-57-5
14
Methylprednisolone Approved, Vet_approved Phase 4,Phase 2,Phase 3 83-43-2 6741
15
Linagliptin Approved Phase 4 668270-12-0 10096344
16
Povidone-iodine Approved Phase 4,Phase 3,Not Applicable 25655-41-8
17
Nepafenac Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 78281-72-8 151075
18
Diclofenac Approved, Vet_approved Phase 4,Phase 1,Not Applicable 15307-86-5 3033
19
Temazepam Approved, Investigational Phase 4,Phase 3,Not Applicable 846-50-4 5391
20
Mycophenolic acid Approved Phase 4,Phase 3 24280-93-1 446541
21
Azathioprine Approved Phase 4 446-86-6 2265
22
Methotrexate Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 59-05-2, 1959-05-2 126941
23
Infliximab Approved Phase 4,Phase 3,Phase 1,Phase 2 170277-31-3
24
Verteporfin Approved, Investigational Phase 4,Phase 1,Phase 2,Not Applicable 129497-78-5
25
Lidocaine Approved, Vet_approved Phase 4,Not Applicable 137-58-6 3676
26
Fluocinolone Acetonide Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Not Applicable,Early Phase 1 67-73-2 6215
27
Ketorolac Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 66635-83-4, 74103-06-3 3826
28
Betamethasone Approved, Vet_approved Phase 4,Phase 2,Phase 3 378-44-9 9782
29
Moxifloxacin Approved, Investigational Phase 4 354812-41-2, 151096-09-2 152946
30 Homatropine Approved Phase 4 87-00-3
31 tannic acid Approved Phase 4,Phase 2,Phase 3,Phase 1
32
Benzocaine Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 94-09-7, 1994-09-7 2337
33
Indomethacin Approved, Investigational Phase 4 53-86-1 3715
34
Travoprost Approved Phase 4 157283-68-6 5282226
35
Bimatoprost Approved, Investigational Phase 4,Phase 3,Phase 2 155206-00-1 5311027
36
Timolol Approved Phase 4,Phase 2,Not Applicable 26839-75-8 33624 5478
37
Latanoprost Approved, Investigational Phase 4,Phase 2 130209-82-4 5311221 5282380
38
Zinc Approved, Investigational Phase 4 7440-66-6
39
Insulin Glargine Approved Phase 4 160337-95-1
40
Chlorambucil Approved Phase 4 305-03-3 2708
41
Cyclophosphamide Approved, Investigational Phase 4 6055-19-2, 50-18-0 2907
42
Prednisone Approved, Vet_approved Phase 4,Phase 3,Phase 2 53-03-2 5865
43
Tacrolimus Approved, Investigational Phase 4,Phase 3 104987-11-3 445643 439492
44
Dinoprost Tromethamine Approved, Vet_approved Phase 4 38562-01-5 5282415
45
Dinoprost Approved, Investigational Phase 4 551-11-1 5283078
46
Fenofibrate Approved Phase 4,Phase 3,Phase 2 49562-28-9 3339
47
leucovorin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 58-05-9 6006 143
48
Difluprednate Approved Phase 4 23674-86-4 443936
49
Fluprednisolone Approved Phase 4 53-34-9
50
Alogliptin Approved Phase 4 850649-61-5 11450633

Interventional clinical trials:

(show top 50) (show all 845)
# Name Status NCT ID Phase Drugs
1 Treatment of Bevacizumab and Triamcinolone in Treatment or Macular Edema Secondary to CRVO Unknown status NCT00566761 Phase 4 bevacizumab and triamcinolone
2 Predictors of Treatment Response to Aflibercept and Aqueous Cytokine Levels in Patients With Persistent Diabetic Macular Edema Following Treatment With Ranibizumab: An Interventional Prospective Study Unknown status NCT02651168 Phase 4
3 Study of Intravitreal Aflibercept Injection for Persistent CRVO-associated Macular Edema Despite Prior Anti-VEGF Therapy Unknown status NCT01857544 Phase 4 Aflibercept
4 Posterior Subtenon Versus Intravitreal Injection of Triamcinolone Acetonide for Treatment of Uveitic Cystoid Macular Edema Unknown status NCT02598869 Phase 4 Triamcinolone Acetonide
5 Effect of Dexamethasone Implant in Hard Exudate Complicated With Diabetic Macular Edema Unknown status NCT02399657 Phase 4 Intravitreal dexamethasone 0.7mg implant
6 The Endurance 1 Trial Unknown status NCT02297204 Phase 4 aflibercept 2.0 mg
7 Bevacizumab and Peripheral Retinal Changes on Wide Field Angiography in Diabetic Macular Edema Unknown status NCT02096874 Phase 4 Bevacizumab
8 POSTERIOR SUB-TENON'S Avastin Unknown status NCT00567372 Phase 4 bevacizumab (Sub-tenon´s injection)
9 To Compare Anti-VEGF Monotherapy With Anti-VEGF and EPM Grid Laser Combination Therapy for Diabetic Macular Edema Unknown status NCT02462304 Phase 4 ranibizumab;Bevacizumab
10 Treatment of Cystoid Macular Edema in Patients With Retinal Degeneration Unknown status NCT00716586 Phase 4 dorzolamide
11 Comparison of the Effects of Bevacizumab Before vs After Pattern Panretinal Photocoagulation Unknown status NCT00804206 Phase 4 bevacizumab;bevacizumab
12 Ozurdex Versus Ranibizumab Versus Combination for Central Retinal Vein Occlusion Unknown status NCT01827722 Phase 4 Ozurdex;Ranibizumab;Combination Ozurdex with Ranibizumab PRN
13 Laser Therapy Combined With Intravitreal Aflibercept vs Intravitreal Aflibercept Monotherapy (LADAMO) Unknown status NCT02432547 Phase 4 Aflibercept
14 Intravitreal Ranibizumab for the Prevention of Radiation Maculopathy Following Plaque Radiotherapy Unknown status NCT00540930 Phase 4 Ranibizumab
15 Evaluation of the "Treat-and-extend" Scheme in Patients With Retinal Vein Occlusion (RVO) With and Without LASER Treatment of Ischaemic Retinal Areas Unknown status NCT02522897 Phase 4 Ranibizumab
16 Comparing Injection Frequency Between Aflibercept and Ranibizumab in Patients With CRVO With a Treat& Extend Regimen Unknown status NCT02274259 Phase 4 Aflibercept;Ranibizumab
17 Changes in Macular Thickness After Patterns Scan Laser Unknown status NCT00563628 Phase 4
18 Thiazolidinedione (TZD) on the Diabetic Retinopathy and Nephropathy Unknown status NCT01175486 Phase 4 Actos (Pioglitazone);Acarbose
19 ALPI vs Medical Therapy Effects on Optic Nerve Structure & Function Unknown status NCT00485238 Phase 4 Intravenous acetazolamide
20 Panretinal Photocoagulation for Proliferative Diabetic Retinopathy in a Single Session Using Low Fluence Parameters Unknown status NCT01023698 Phase 4
21 Randomized, Masked Comparison of Bromfenac and Besifloxacin BID With Either Prednisolone BID or Loteprednol 0.5% BID for Prevention of Retinal Thickening and CME Following Phacoemulsification Unknown status NCT01193504 Phase 4 Pred Forte;Lotemax
22 A One-year Randomized Controlled Trial Evaluating the Impact of Pioglitazone Versus Linagliptin on Bone Turnover Markers Unknown status NCT02429232 Phase 4 Pioglitazone;Linagliptin
23 Intraocular Anti-VEGF Compared With Intraocular Triamcinolone in Patients With Diabetic Macular Edema Completed NCT00682539 Phase 4 Bevacizumab (Avastin);Triamcinolone;Sham
24 Intravitreal Macugen for Ischaemic Diabetic Macular Oedema Completed NCT01175070 Phase 4 Intravitreal injection of pegaptanib sodium
25 Efficacy of Ranibizumab Therapy With Aflibercept in Patients With Diabetic Macular Edema Completed NCT02646670 Phase 4 Ranibizumab;Aflibercept;Ranibizumab and Aflibercept;Aflibercept and ranibizumab
26 Multicenter Study to Evaluate the Efficacy of Treat and Extend Regimen of Aflibercept (EYLEA) as a Second Line Treatment for Diabetic Macular Edema Completed NCT02633852 Phase 4 Aflibercept
27 Ozurdex for Diabetic Macular Edema Treated With Pars Plana vitrEctomy and Membrane RemovAl (OPERA Study) Completed NCT01613716 Phase 4 Ozurdex
28 A Pilot Study on the Effect and Safety of Iluvien® in Chronic Diabetic Macular Edema Patients Completed NCT02359526 Phase 4 IlUVIEN
29 Topical Nepafenac as Supplement for Diabetic Macular Edema Completed NCT02443012 Phase 4 Topical Gutt Nepafenac 0.1%
30 TAHOE: Intravitreal Dexamethasone Implant (Ozurdex) for Uveitic Macular Edema Completed NCT01870440 Phase 4 Ozurdex Intravitreal Injection (0.7 mg)
31 Efficacy Study of Triamcinolone and Bevacizumab Intravitreal for Treatment of Diabetic Macular Edema Completed NCT00737971 Phase 4 Bevacizumab intravitreal;Triamcinolone;Triamcinolone + Bevacizumab
32 Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Alone Versus Ozurdex Given Every 3 Months for Treatment of Persistent Diabetic Macular Edema Completed NCT02036424 Phase 4 Ozurdex;Bevacizumab
33 Ranibizumab Treatment of Diabetic Macular Oedema With Bimonthly Monitoring After a Phase of Initial Treatment Completed NCT01257815 Phase 4 Ranibizumab
34 Long-Term Efficacy and Safety of Intravitreal Aflibercept Injections for the Treatment of Diabetic Macular Edema in Subjects Who Completed the Three Year VISTA-DME Trial (The Endurance 2 Trial) Completed NCT02368756 Phase 4 Aflibercept
35 Anti-inflammatory Efficacy for Prophylaxis of Cystoid Macular Edema (CME) After Phacoemulsification Completed NCT02084576 Phase 4 Nepafenac;Ketorolac
36 A Study Evaluating Dosing Regimens for Treatment With Intravitreal Ranibizumab Injections in Subjects With Macular Edema Following Retinal Vein Occlusion Completed NCT01277302 Phase 4 Ranibizumab
37 Randomized, Double Blind Trial of Bromfenac BID (0.09%) as an Adjunct to Argon Laser Therapy in the Treatment of Diabetic Macular Edema. Completed NCT00758628 Phase 4 Bromefenac;Blink
38 Ozurdex as Adjunct to Avastin Compared to Avastin Alone in Treatment of Patients With Diabetic Macular Edema Completed NCT01309451 Phase 4 Bevacizumab;dexamethasone intravitreal implant
39 Avastin for Post-Photocoagulation Macular Edema Completed NCT00801866 Phase 4 Bevacizumab
40 Early Anatomical, Physiological, and Clinical Changes in Diabetic Macular Edema After Intravitreal Aflibercept Injection Completed NCT03453281 Phase 4 Aflibercept Injection [Eylea]
41 Unilateral Bevacizumab for Bilateral Diabetic Macular Edema Completed NCT00496405 Phase 4 bevacizumab
42 NEWTON: Aflibercept Injection for Previously Treated Macular Edema Associated With Central Retinal Vein Occlusions Completed NCT01870427 Phase 4 Aflibercept (2.0 mg)
43 Investigation of the Change of Vision-related Quality of Life in Subjects Treated With Aflibercept According to EU Label for DME. Completed NCT02581995 Phase 4 Eylea (Aflibercept, VEGF Trap-Eye, BAY86-5321)
44 CME With Different Fluidic Parameters Completed NCT01385852 Phase 4
45 Prophylactic Nepafenac and Ketorolac Versus Placebo in Patients Undergoing Cataract Surgery Completed NCT01395069 Phase 4 Nepafenac 0.1%;Ketorolac 0.5%
46 Bromfenac BID Plus Prednisolone Acetate BID Versus Bromfenac BID Plus Prednisolone QID for the Prevention of Cystoid Macular Edema and Retinal Thickening Completed NCT00469781 Phase 4 2. Xibrom (Bromfenac);1. Pred Forte
47 A Clinical Study in Current Medical Practice of the Efficacy and Safety of Ranibizumab 0.5mg in Diabetic Patients Presenting a Visual Impairment Due to Macular Edema Completed NCT01315275 Phase 4 Ranibizumab
48 Intraoperative Dexamethasone Implant Improves Outcome of Cataract Surgery With Diabetic Macular Edema Completed NCT01546402 Phase 4 Dexamethasone Drug delivery system (Ozurdex)
49 Evaluation of Macugen Treatment of Macular Edema Due to Branch Retinal Vein Occlusion Completed NCT00406107 Phase 4 pegaptanib sodium (Macugen)
50 Ranibizumab "Treat and Extend" in Diabetic Macular Edma Completed NCT01297569 Phase 4 Ranibizumab

Search NIH Clinical Center for Macular Retinal Edema

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Genetic Tests for Macular Retinal Edema

Genetic tests related to Macular Retinal Edema:

# Genetic test Affiliating Genes
1 Macular Edema 29

Anatomical Context for Macular Retinal Edema

MalaCards organs/tissues related to Macular Retinal Edema:

41
Eye, Endothelial, Retina, Testes, Bone, Myeloid, Brain

Publications for Macular Retinal Edema

Articles related to Macular Retinal Edema:

(show top 50) (show all 2835)
# Title Authors Year
1
Comparison of the Efficacy of Sub-Tenon versus Intravitreal Triamcinolone Acetonide Injection during Cataract Surgery for Diabetic Macular Edema. ( 30041252 )
2019
2
Effectiveness and Safety of Intravitreal Dexamethasone Implant (Ozurdex) in Patients with Diabetic Macular Edema: A Real-World Experience. ( 30408801 )
2019
3
Short-term outcomes after the loading phase of intravitreal bevacizumab and subthreshold macular laser in non-center involved diabetic macular edema. ( 29977811 )
2018
4
Comparison of Intravitreal Aflibercept and Ranibizumab following Initial Treatment with Ranibizumab in Persistent Diabetic Macular Edema. ( 29850202 )
2018
5
A 5-Year Follow-Up Study of the Treatment of Macular Edema Due to Retinal Vein Occlusion Using Dexamethasone Intravitreal Implants. ( 29708803 )
2018
6
Aflibercept for clinically significant diabetic macular edema: 12-month results in daily clinical practice. ( 29386883 )
2018
7
Efficiency of fenofibrate in facilitating the reduction of central macular thickness in diabetic macular edema. ( 29283132 )
2018
8
Anti-Vascular Endothelial Growth Factor Therapy in Diabetic Macular Edema: Does Flavor Matter? ( 29392302 )
2018
9
Diabetic macular edema treated with ranibizumab following bevacizumab failure in Israel (DERBI study). ( 29916263 )
2018
10
Treatment Efficacy and Compliance in Patients with Diabetic Macular Edema Treated with Ranibizumab in a Real-Life Setting. ( 29850205 )
2018
11
Comparison of the Efficacy of Dexamethasone, Nepafenac, and Bromfenac for Preventing Pseudophakic Cystoid Macular Edema: an Open-label, Prospective, Randomized Controlled Trial. ( 29120255 )
2018
12
Visual Outcomes Based on Early Response to Anti-Vascular Endothelial Growth Factor Treatment for Diabetic Macular Edema. ( 29316563 )
2018
13
Comparing Cytokine Kinetics between Ranibizumab and Aflibercept in Central Retinal Vein Occlusion with Macular Edema. ( 29804112 )
2018
14
One-Year Outcome of Conbercept Therapy for Diabetic Macular Edema. ( 29265939 )
2018
15
Macular Edema in Childhood Uveitis. ( 29452454 )
2018
16
Intravitreal dexamethasone implants for diabetic macular edema. ( 29375995 )
2018
17
Markers of poor glycemic control are helpful to assess the risk of pseudophakic macular edema in diabetic cataract surgery patients. ( 29703307 )
2018
18
Management of diabetic macular edema with intravitreal dexamethasone implants: Expert recommendations using a Delphi-based approach. ( 29882421 )
2018
19
Multimodal Imaging in Diabetic Macular Edema. ( 29376234 )
2018
20
Real-life experience of ranibizumab for diabetic macular edema in Taiwan. ( 29926364 )
2018
21
The efficacy of intravitreal dexamethasone implant as the first-line treatment for retinal vein occlusion-related macular edema in a real-life scenario. ( 29785994 )
2018
22
Targeted Retinal Photocoagulation for Diabetic Macular Edema with Peripheral Retinal Nonperfusion: Three-Year Randomized DAVE Trial. ( 29336896 )
2018
23
Effect of oral tranexamic acid on macular edema associated with retinal vein occlusion or diabetes. ( 29339919 )
2018
24
Choroidal Thickness in Diabetic Macular Edema Compared to Normal Controls. ( 29944846 )
2018
25
The short-term efficacy of intravitreal ranibizumab, aflibercept and dexamethasone implant in the treatment of macular edema due to non-ischemic central retinal vein occlusion. ( 29550932 )
2018
26
Early Retinal and Choroidal Coat Thickness Changes After Intravitreal Dexamethasone Implant Injection for Diabetic Macular Edema. ( 29866639 )
2018
27
Basis and Design of a Randomized Clinical Trial to Evaluate the Effect of Levosulpiride on Retinal Alterations in Patients With Diabetic Retinopathy and Diabetic Macular Edema. ( 29896154 )
2018
28
Detailed analysis of retinal morphology in patients with diabetic macular edema (DME) randomized to ranibizumab or triamcinolone treatment - reply to the letter to the editor. ( 29368041 )
2018
29
Safety and efficacy of dexamethasone intravitreal implant for treatment of macular edema secondary to retinal vein occlusion in Chinese patients: randomized, sham-controlled, multicenter study. ( 29399708 )
2018
30
Eplerenone, a new treatment for an old problem: Retinitis pigmentosa with recalcitrant macular edema. ( 28624313 )
2018
31
Pharmacology of Corticosteroids for Diabetic Macular Edema. ( 29297055 )
2018
32
Evaluation of the effect of combined intravitreal ranibizumab injection and sub-tenon steroid injection in the treatment of resistant diabetic macular edema. ( 29943100 )
2018
33
Apelin-13 Is an Early Promoter of Cytoskeleton and Tight Junction in Diabetic Macular Edema via PI-3K/Akt and MAPK/Erk Signaling Pathways. ( 29850504 )
2018
34
Is it melanoma-associated retinopathy or drug toxicity? Bilateral cystoid macular edema posing a diagnostic and therapeutic dilemma. ( 29780921 )
2018
35
Treatment of cystoid macular edema in homozygous twins with glutathione synthetase deficiency and retinal dystrophy. ( 29395598 )
2018
36
Aflibercept Versus Bevacizumab and/or Ranibizumab for Recurrent Macular Edema Secondary to Central Retinal Vein Occlusion. ( 29447089 )
2018
37
Prevalence of diabetic retinopathy and diabetic macular edema in a primary care-based teleophthalmology program for American Indians and Alaskan Natives. ( 29924846 )
2018
38
Evaluation of Navigated Laser Photocoagulation (Navilas 577+) for the Treatment of Refractory Diabetic Macular Edema. ( 29854426 )
2018
39
ILUVIEN<sup>Ar</sup> technology in the treatment of center-involving diabetic macular edema: a review of the literature. ( 29943691 )
2018
40
Quantitative assessment of macular contraction and vitreoretinal interface alterations in diabetic macular edema treated with intravitreal anti-VEGF injections. ( 29922890 )
2018
41
Safety and long-term efficacy of repeated dexamethasone intravitreal implants for the treatment of cystoid macular edema secondary to retinal vein occlusion with or without a switch to anti-VEGF agents: a 3-year experience. ( 29855706 )
2018
42
Correlation between macular ganglion cell-inner plexiform layer thickness and visual acuity after resolution of the macular edema secondary to central retinal vein occlusion. ( 29487816 )
2018
43
Oral administration of a curcumin-phospholipid formulation (MerivaAr) for treatment of chronic diabetic macular edema: a pilot study. ( 29917217 )
2018
44
Persistent Macular Thickening Following Intravitreous Aflibercept, Bevacizumab, or Ranibizumab for Central-Involved Diabetic Macular Edema With Vision Impairment: A Secondary Analysis of a Randomized Clinical Trial. ( 29392288 )
2018
45
Evaluation of contrast sensitivity and other visual function outcomes in diabetic macular edema patients following treatment switch to aflibercept from ranibizumab. ( 29403260 )
2018
46
Comparison of the Effect of Intravitreal Dexamethasone Implant in Vitrectomized and Nonvitrectomized Eyes for the Treatment of Diabetic Macular Edema. ( 29850199 )
2018
47
Association Between Soluble CD14 in the Aqueous Humor and Hyperreflective Foci on Optical Coherence Tomography in Patients With Diabetic Macular Edema. ( 29392317 )
2018
48
Impact of Early Anatomical and Functional Responses to Bevacizumab in Macular Edema Secondary to Branch Retinal Vein Occlusion. ( 29393235 )
2018
49
Vision Outcomes Following Anti-Vascular Endothelial Growth Factor Treatment of Diabetic Macular Edema in Clinical Practice. ( 29970221 )
2018
50
Evaluation of Vitrectomy with Planned Foveal Detachment as Surgical Treatment for Refractory Diabetic Macular Edema with or without Vitreomacular Interface Abnormality. ( 29854429 )
2018

Variations for Macular Retinal Edema

Expression for Macular Retinal Edema

Search GEO for disease gene expression data for Macular Retinal Edema.

Pathways for Macular Retinal Edema

GO Terms for Macular Retinal Edema

Biological processes related to Macular Retinal Edema according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 visual perception GO:0007601 9.61 BEST1 MFRP PDE6A
2 response to hypoxia GO:0001666 9.58 ICAM1 KCNMA1 VEGFA
3 cellular response to lipopolysaccharide GO:0071222 9.54 CCL2 ICAM1 IL6
4 regulation of cell shape GO:0008360 9.5 CCL2 ICAM1 VEGFA
5 cytokine-mediated signaling pathway GO:0019221 9.46 CCL2 ICAM1 IL6 VEGFA
6 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.43 ICAM1 IL6 VEGFA
7 ovarian follicle development GO:0001541 9.13 FANCG ICAM1 VEGFA
8 eye photoreceptor cell development GO:0042462 8.8 CRB1 MFRP VEGFA

Sources for Macular Retinal Edema

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....